Fresh Tracks Therapeutics Inc Investor Relations Material

Latest events

Q3 2022

Fresh Tracks Therapeutics Inc

Q3 2023

13 Nov, 2023

Q2 2023

10 Aug, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Fresh Tracks Therapeutics Inc

Access all reports
Fresh Tracks Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. It develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases. The company has license agreements with Carna Biosciences Ltd., Voronoi Inc., Bodor Laboratories Inc., Dr. Nicholas S. Bodor and AnGes, Inc.